Zeltia Group Shares Soar After Cancer Drug Approval

July 20, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MADRID, July 20 (Reuters) - Shares in Spanish drug company Zeltia (ZEL.MC: Quote, Profile, Research) soared on Friday after its cancer treatment Yondelis was recommended for approval in Europe, its first medicine to make its way to the market.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Europe